Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tripotassium dicitrato bismuthate/tetracycline/metronidazole

Drug Profile

Tripotassium dicitrato bismuthate/tetracycline/metronidazole

Alternative Names: Biskalcitrate potassium 140mg/metronidazole 125mg/tetracycline hydrochloride 125mg; Bismuth subcitrate/metronidazole/tetracycline - Adare Pharmaceuticals; Bismuth-based triple therapy - Adare Pharmaceuticals; Bismuth/metronidazole/tetracycline; Helicide; Helizide; Pylera

Latest Information Update: 10 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axcan Pharma
  • Developer Adare Pharmaceuticals; Aptalis
  • Class Cytoprotectives; Helicobacter pylori eradication therapies; Nitroimidazoles; Organometallic compounds; Tetracyclines
  • Mechanism of Action DNA synthesis inhibitors; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Helicobacter infections

Most Recent Events

  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 01 Apr 2015 Launched for Helicobacter infections (Combination therapy) in Germany, Kuwait, Lebanon, Poland and Qatar prior to April 2015 (PO)
  • 01 Apr 2015 No recent reports on development identified - Registered for Helicobacter infections (Combination therapy) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top